Ophthalmology
Partner With Us
Advertisement
Conexiant chevron_right Ophthalmology chevron_right LIGHTSITE III Data Answers and Raises Questions about Photobiomodulation Therapy for AMD
From the Journals

LIGHTSITE III Data Answers and Raises Questions about Photobiomodulation Therapy for AMD

The trial met the primary endpoint with a statistically significant +5.4 letter gain in BCVA and a favorable safety profile, but experts raised additional questions after the FDA cleared marketing for a PBM device.

Conexiant
article Full Article subject Summary summarize Notecard
  1. LIGHTSITE III evaluated multiwavelength photobiomodulation (PBM) therapy for dry AMD.
  2. PBM-treated eyes showed statistically significant visual improvements, as well as functional benefits. 
  3. PBM-treated eyes had a significantly lower rate of new geographic atrophy lesions.
  4. Future research should explore broader patient populations for PBM efficacy.

Source: Retina

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.